Studies with a New Generation of Oral Attenuated Shigella Vaccine: Escherichia coli Bearing Surface Antigens of Shigella flexneri

In an attempt to develop a safe, proliferating, oral, attenuated vaccine against shigellosis, genes that control the synthesis of group- and type-specific somatic antigens of Shigella flexneri 2a were transferred via conjugation to a recipient strain of Escherichia coli. The resultant hybrid (E. col...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1977-10, Vol.136 (4), p.577-582
Main Authors: Levine, Myron M., Woodward, William E., Formal, Samuel B., Gemski, Peter, DuPont, Herbert L., Hornick, Richard B., Snyder, Merrill J.
Format: Article
Language:English
Subjects:
Administration, Oral
Antibodies
Antigens
Antigens, Bacterial
Bacillary dysentery
Bacterial Vaccines - administration & dosage
Dosage
Escherichia coli - genetics
Hybridity
Major Articles
Shigella
Shigella flexneri
Shigella flexneri - genetics
Shigella flexneri - immunology
Shigella vaccine
Transformation, Bacterial
Vaccination
Vaccines, Attenuated
Volunteerism
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In an attempt to develop a safe, proliferating, oral, attenuated vaccine against shigellosis, genes that control the synthesis of group- and type-specific somatic antigens of Shigella flexneri 2a were transferred via conjugation to a recipient strain of Escherichia coli. The resultant hybrid (E. coli expressing shigella surface antigens) vaccine strain, PGAI 42-1-15, believed to have a complete (smooth) lipopolysaccharide, was given to volunteers in two vaccination-challenge studies. The vaccine was well tolerated and gave evidence of intestinal proliferation. In trial no. 1, volunteers given two doses of vaccine one month apart were challenged after eight weeks with 104 virulent S. flexneri 2a. Attack rates were comparable in vaccinees (50%) and controls (40%). In trial no. 2, vaccinees were given three weekly doses of vaccine and were challenged four weeks later with a small inoculum (102) of S. flexneri 2a. Again, attack rates among vaccinees (47%) and controls (39%) were similar. It is unclear why this theoretically ideal, live shigella vaccine failed to protect against S. flexneri 2a.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/136.4.577